HOUSTON, TX – DM Clinical Research is celebrating two decades of advancing clinical research, a milestone that underscores its role in expanding patient access to innovative therapies across the United States. Founded in 2006 with a vision to make clinical trials more accessible and patient-centered, the organization has grown into one of the nation's leading integrated clinical research networks.
Over the past 20 years, DM Clinical has significantly expanded its national footprint, therapeutic expertise, and research capabilities. Today, it operates more than 35 research sites and provides access to a patient population of 1.97 million individuals across 32 therapeutic areas. Since its inception, the network has enrolled more than 35,000 patients in clinical trials, contributing to the development of safe, life-changing therapies for patients worldwide.
“Reaching 20 years is incredibly meaningful to me,” said Mohammad Millwala, Founder and CEO of DM Clinical Research. “When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey. We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference.”
The company’s growth has been driven by its partnerships with leading pharmaceutical, biotechnology, and healthcare organizations, as well as contract research organizations (CROs). DM Clinical focuses on delivering strong enrollment performance, diverse patient access, and operational excellence. Its integrated operating model combines local physician relationships with centralized infrastructure to ensure quality, speed, and consistent execution for sponsors and CRO partners.
A key aspect of DM Clinical’s mission is expanding access to clinical research in underserved communities. This effort ensures that more patients, regardless of their background or location, have the opportunity to participate in trials that could benefit their health. By continuing to grow its presence in these communities, DM Clinical is helping to address disparities in clinical trial participation and bring the benefits of research to a broader population.
The company’s commitment to excellence has been recognized through several industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE’s Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, Millwala was also honored with the SCRS Christine K. Pierre Site Impact Award for his leadership and contributions to the field.
As DM Clinical enters its third decade, its 20th anniversary theme, “Champions of Clinical Research: 20 Years of Impact,” reflects the teamwork and innovation that have fueled its success. The company plans to continue expanding into new communities, broadening its therapeutic expertise, and investing in innovative technologies to improve patient access to clinical trials.
“As we celebrate this milestone, we remain focused on what's next,” added Millwala. “The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives.”
The importance of this anniversary extends beyond the company itself. Clinical trials are essential for developing new treatments, but patient enrollment remains a significant challenge. By growing its network and focusing on underserved populations, DM Clinical is helping to make trials more inclusive and efficient, which can accelerate the delivery of new therapies to patients who need them. Its two decades of operation demonstrate a sustained commitment to this critical mission, with implications for the future of medical research and patient care.
